{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:38:03Z","timestamp":1773956283333,"version":"3.50.1"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-025-11349-7","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T11:33:50Z","timestamp":1765366430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non-Coding RNAs and cernas: emerging modulators of drug response in colorectal cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Elahe","family":"Shams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elahe Daskar","family":"Abkenar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Negin","family":"Sina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona Malekzadeh","family":"Moghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Nobili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan Nazemalhosseini","family":"Mojarad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayeralsadat","family":"Fatemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"issue":"3","key":"11349_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 74(3):229\u201363","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"7","key":"11349_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071732","volume":"14","author":"MS Hossain","year":"2022","unstructured":"Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi DJ, John A et al (2022) Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers 14(7):1732","journal-title":"Cancers"},{"key":"11349_CR3","unstructured":"Benson AB, Venook AP, Adam M, Chang G, Chen Y-J, Ciombor KK et al (2024) Colon Cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 22(2D)"},{"issue":"2","key":"11349_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4251\/wjgo.v15.i2.251","volume":"15","author":"JE Olguin","year":"2023","unstructured":"Olguin JE, Mendoza-Rodriguez MG, Sanchez-Barrera CA, Terrazas LI (2023) Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment? World J Gastrointest Oncol 15(2):251","journal-title":"World J Gastrointest Oncol"},{"issue":"2","key":"11349_CR5","first-page":"185","volume":"6","author":"P Yaffee","year":"2015","unstructured":"Yaffee P, Osipov A, Tan C, Tuli R, Hendifar A (2015) Review of systemic therapies for locally advanced and metastatic rectal cancer. J Gastrointest Oncol 6(2):185","journal-title":"J Gastrointest Oncol"},{"issue":"6","key":"11349_CR6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40259-018-0322-1","volume":"32","author":"WC Da Silva","year":"2018","unstructured":"Da Silva WC, De Araujo VE, Lima EMA, Dos Santos JBR, Silva MRRd, Almeida PHRF et al (2018) Comparative effectiveness and safety of monoclonal antibodies (bevacizumab, cetuximab, and panitumumab) in combination with chemotherapy for metastatic colorectal cancer: a systematic review and meta-analysis. BioDrugs 32(6):585\u2013606","journal-title":"BioDrugs"},{"issue":"9","key":"11349_CR7","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3748\/wjg.v29.i9.1395","volume":"29","author":"S Al Bitar","year":"2023","unstructured":"Al Bitar S, El-Sabban M, Doughan S, Abou-Kheir W (2023) Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: updates and beyond. World J Gastroenterol 29(9):1395","journal-title":"World J Gastroenterol"},{"key":"11349_CR8","doi-asserted-by":"crossref","unstructured":"Lee W (2024) MicroRNAs and other Non-Coding RNAs as Regulators, Biomarkers, and therapeutic targets. MDPI, p 3998","DOI":"10.3390\/ijms25073998"},{"key":"11349_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.951864","volume":"12","author":"X Zhou","year":"2022","unstructured":"Zhou X, Ao X, Jia Z, Li Y, Kuang S, Du C et al (2022) Non-coding RNA in cancer drug resistance: underlying mechanisms and clinical applications. Frontiers in oncology 12:951864","journal-title":"Frontiers in oncology"},{"issue":"11","key":"11349_CR10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.5732\/cjc.013.10170","volume":"32","author":"T Huang","year":"2013","unstructured":"Huang T, Alvarez A, Hu B, Cheng S-Y (2013) Noncoding RNAs in cancer and cancer stem cells. Chin J Cancer 32(11):582","journal-title":"Chin J Cancer"},{"issue":"6","key":"11349_CR11","doi-asserted-by":"publisher","first-page":"924","DOI":"10.4161\/rna.24604","volume":"10","author":"L Ma","year":"2013","unstructured":"Ma L, Bajic VB, Zhang Z (2013) On the classification of long non-coding RNAs. RNA Biol 10(6):924\u2013933","journal-title":"RNA Biol"},{"key":"11349_CR12","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s13277-015-3870-8","volume":"37","author":"Y Wu","year":"2016","unstructured":"Wu Y, Lu W, Xu J, Shi Y, Zhang H, Xia D (2016) Prognostic value of long non-coding RNA MALAT1 in cancer patients. Tumor Biol 37:897\u2013903","journal-title":"Tumor Biol"},{"issue":"4","key":"11349_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.18388\/abp.2012_2079","volume":"59","author":"P Tokarz","year":"2012","unstructured":"Tokarz P, Blasiak J (2012) The role of MicroRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochim Pol 59(4):467\u2013474","journal-title":"Acta Biochim Pol"},{"issue":"10","key":"11349_CR14","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/jmedgenet-2015-103334","volume":"52","author":"X Qi","year":"2015","unstructured":"Qi X, Zhang D-H, Wu N, Xiao J-H, Wang X, Ma W (2015) CeRNA in cancer: possible functions and clinical implications. J Med Genet 52(10):710\u2013718","journal-title":"J Med Genet"},{"issue":"sup2","key":"11349_CR15","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1517\/14728222.2011.650632","volume":"16","author":"LR Corsini","year":"2012","unstructured":"Corsini LR, Bronte G, Terrasi M, Amodeo V, Fanale D, Fiorentino E et al (2012) The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin Ther Targets 16(sup2):S103\u2013S9","journal-title":"Expert Opin Ther Targets"},{"issue":"7","key":"11349_CR16","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1158\/1055-9965.EPI-11-0035","volume":"20","author":"X Luo","year":"2011","unstructured":"Luo X, Burwinkel B, Tao S, Brenner H (2011) MicroRNA signatures: novel biomarker for colorectal cancer? Cancer Epidemiol Biomarkers Prev 20(7):1272\u201386","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"11349_CR17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1254\/jphs.10R12FM","volume":"114","author":"Y Kitade","year":"2010","unstructured":"Kitade Y, Akao Y (2010) MicroRNAs and their therapeutic potential for human diseases: microRNAs, miR-143 and-145, function as anti-oncomirs and the application of chemically modified miR-143 as an anti-cancer drug. J Pharmacol Sci 114(3):276\u2013280","journal-title":"J Pharmacol Sci"},{"key":"11349_CR18","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.3389\/fphar.2019.01500","volume":"10","author":"N Nik Mohamed Kamal","year":"2019","unstructured":"Nik Mohamed Kamal N, Shahidan WNS (2019) Non-exosomal and exosomal circulatory micrornas: which are more valid as biomarkers? Front Pharmacol 10:1500","journal-title":"Front Pharmacol"},{"key":"11349_CR19","unstructured":"Fromm B, Domanska D, Hackenberg M, Mathelier A, H\u00f8ye E, Johansen M et al (2018) MirGeneDB2. 0: the curated microRNA gene database. BioRxiv 258749"},{"key":"11349_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117973","volume":"256","author":"M Ashrafizadeh","year":"2020","unstructured":"Ashrafizadeh M, Zarrabi A, Hushmandi K, Hashemi F, Hashemi F, Samarghandian S, Najafi M (2020) MicroRNAs in cancer therapy: their involvement in oxaliplatin sensitivity\/resistance of cancer cells with a focus on colorectal cancer. Life Sci 256:117973","journal-title":"Life Sci"},{"issue":"9","key":"11349_CR21","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3390\/biology10090854","volume":"10","author":"S Azwar","year":"2021","unstructured":"Azwar S, Seow HF, Abdullah M, Faisal Jabar M, Mohtarrudin N (2021) Recent updates on mechanisms of resistance to 5-fluorouracil and reversal strategies in colon cancer treatment. Biol 10(9):854","journal-title":"Biol"},{"issue":"3","key":"11349_CR22","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1002\/jcp.27221","volume":"234","author":"RM Marjaneh","year":"2019","unstructured":"Marjaneh RM, Khazaei M, Ferns GA, Avan A, Aghaee-Bakhtiari SH (2019) The role of MicroRNAs in 5-FU resistance of colorectal cancer: possible mechanisms. J Cell Physiol 234(3):2306\u20132316","journal-title":"J Cell Physiol"},{"issue":"3","key":"11349_CR23","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20190249","volume":"39","author":"G Liu","year":"2019","unstructured":"Liu G, Zhou J, Dong M (2019) Down-regulation of miR-543 expression increases the sensitivity of colorectal cancer cells to 5-fluorouracil through the PTEN\/PI3K\/AKT pathway. Biosci Rep 39(3):BSR20190249","journal-title":"Biosci Rep"},{"key":"11349_CR24","doi-asserted-by":"crossref","unstructured":"Xian Z, Hu B, Wang T, Zeng J, Cai J, Zou Q, Zhu P (2020) LncRNA UCA1 contributes to 5-fluorouracil resistance of colorectal cancer cells through miR-23b-3p\/ZNF281 axis. OncoTargets Therapy 7571\u20137583","DOI":"10.2147\/OTT.S258727"},{"issue":"5","key":"11349_CR25","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1111\/cas.14356","volume":"111","author":"F Xu","year":"2020","unstructured":"Xu F, Ye ML, Zhang YP, Li WJ, Li MT, Wang HZ et al (2020) MicroRNA-375\u20103p enhances chemosensitivity to 5\u2010fluorouracil by targeting thymidylate synthase in colorectal cancer. Cancer Sci 111(5):1528\u201341","journal-title":"Cancer Sci"},{"issue":"2","key":"11349_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2022.5304","volume":"60","author":"S Pan","year":"2022","unstructured":"Pan S, Deng Y, Fu J, Zhang Y, Zhang Z, Qin X (2022) N6\u2013methyladenosine upregulates miR\u2013181d\u20135p in exosomes derived from cancer\u2013associated fibroblasts to inhibit 5\u2013FU sensitivity by targeting NCALD in colorectal cancer. Int J Oncol 60(2):1\u201317","journal-title":"Int J Oncol"},{"issue":"4","key":"11349_CR27","first-page":"4064","volume":"18","author":"L Zhang","year":"2019","unstructured":"Zhang L, Li B, Zhang B, Zhang H, Suo J (2019) miR\u2013361 enhances sensitivity to 5\u2013fluorouracil by targeting the FOXM1\u2013ABCC5\/10 signaling pathway in colorectal cancer. Oncol Lett 18(4):4064\u20134073","journal-title":"Oncol Lett"},{"issue":"2","key":"11349_CR28","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.4081\/ejh.2021.3247","volume":"65","author":"S Wu","year":"2021","unstructured":"Wu S, Zhou Y, Liu P, Zhang H, Wang W, Fang Y, Shen X (2021) MicroRNA-29b-3p promotes 5-fluorouracil resistance via suppressing TRAF5-mediated necroptosis in human colorectal cancer. Eur J Histochemistry: EJH 65(2):3247","journal-title":"Eur J Histochemistry: EJH"},{"issue":"11","key":"11349_CR29","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1038\/s41418-022-01007-x","volume":"29","author":"Y Yang","year":"2022","unstructured":"Yang Y, Yuan H, Zhao L, Guo S, Hu S, Tian M et al (2022) Targeting the miR-34a\/LRPPRC\/MDR1 axis collapse the chemoresistance in P53 inactive colorectal cancer. Cell Death Differ 29(11):2177\u20132189","journal-title":"Cell Death Differ"},{"issue":"6","key":"11349_CR30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/jb\/mvaa012","volume":"167","author":"Z-Y Xie","year":"2020","unstructured":"Xie Z-Y, Wang F-F, Xiao Z-H, Liu S-F, Tang S-L, Lai Y-L (2020) Overexpressing microRNA-34a overcomes ABCG2-mediated drug resistance to 5-FU in side population cells from colon cancer via suppressing DLL1. J Biochem 167(6):557\u2013564","journal-title":"J Biochem"},{"issue":"10","key":"11349_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101576","volume":"11","author":"H-H Hsu","year":"2019","unstructured":"Hsu H-H, Kuo W-W, Shih H-N, Cheng S-F, Yang C-K, Chen M-C et al (2019) FOXC1 regulation of miR-31-5p confers oxaliplatin resistance by targeting LATS2 in colorectal cancer. Cancers 11(10):1576","journal-title":"Cancers"},{"issue":"24","key":"11349_CR32","doi-asserted-by":"publisher","first-page":"6037","DOI":"10.7150\/jca.34650","volume":"10","author":"Y Liang","year":"2019","unstructured":"Liang Y, Zhu D, Zhu L, Hou Y, Hou L, Huang X et al (2019) Dichloroacetate overcomes oxaliplatin chemoresistance in colorectal cancer through the miR-543\/PTEN\/Akt\/mTOR pathway. J Cancer 10(24):6037\u201347","journal-title":"J Cancer"},{"issue":"7","key":"11349_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3178","volume":"22","author":"YZ Wu","year":"2020","unstructured":"Wu YZ, Lin HY, Zhang Y, Chen WF (2020) miR-200b\u20103p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer. J Gene Med 22(7):e3178","journal-title":"J Gene Med"},{"issue":"9","key":"11349_CR34","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1016\/j.ymthe.2021.04.028","volume":"29","author":"T Ning","year":"2021","unstructured":"Ning T, Li J, He Y, Zhang H, Wang X, Deng T et al (2021) Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer. Mol Ther 29(9):2723\u20132736","journal-title":"Mol Ther"},{"key":"11349_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.638537","volume":"11","author":"X-L Qian","year":"2021","unstructured":"Qian X-L, Zhou F, Xu S, Jiang J, Chen Z-P, Wang S-K et al (2021) MiR-454-3p promotes oxaliplatin resistance by targeting PTEN in colorectal cancer. Front Oncol 11:638537","journal-title":"Front Oncol"},{"key":"11349_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110517","volume":"101","author":"J Deng","year":"2023","unstructured":"Deng J, Wang H, Liang Y, Zhao L, Li Y, Yan Y et al (2023) miR-15a-5p enhances the malignant phenotypes of colorectal cancer cells through the STAT3\/TWIST1 and PTEN\/AKT signaling pathways by targeting SIRT4. Cell Signal 101:110517","journal-title":"Cell Signal"},{"issue":"1","key":"11349_CR37","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1080\/21691401.2019.1569530","volume":"47","author":"H Liang","year":"2019","unstructured":"Liang H, Xu Y, Zhang Q, Yang Y, Mou Y, Gao Y et al (2019) MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells. Artificial Cells, Nanomedicine, and Biotechnology 47(1):725\u201336","journal-title":"Artificial Cells, Nanomedicine, and Biotechnology"},{"key":"11349_CR38","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8394574","volume":"2020","author":"W Han","year":"2020","unstructured":"Han W, Yin H, Ma H, Wang Y, Kong D, Fan Z (2020) Curcumin regulates ERCC1 expression and enhances oxaliplatin sensitivity in resistant colorectal cancer cells through its effects on miR-409-3p. Evid Based Complement Alternat Med 2020:8394574","journal-title":"Evid Based Complement Alternat Med"},{"issue":"1","key":"11349_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2019.111597","volume":"385","author":"L Lv","year":"2019","unstructured":"Lv L, Li Q, Chen S, Zhang X, Tao X, Tang X et al (2019) miR-133b suppresses colorectal cancer cell stemness and chemoresistance by targeting methyltransferase DOT1L. Exp Cell Res 385(1):111597","journal-title":"Exp Cell Res"},{"key":"11349_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107355","volume":"92","author":"M Azar","year":"2021","unstructured":"Azar M, Aghazadeh H, Mohammed HN, Sara MRS, Hosseini A, Shomali N et al (2021) miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and oxaliplatin chemoresistance by targeting CXCR4. Int Immunopharmacol 92:107355","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"11349_CR41","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.3390\/cells8091111","volume":"8","author":"D Poel","year":"2019","unstructured":"Poel D, Boyd LNC, Beekhof R, Schelfhorst T, Pham TV, Piersma SR et al (2019) Proteomic analysis of miR-195 and miR-497 replacement reveals potential candidates that increase sensitivity to oxaliplatin in MSI\/P53wt colorectal cancer cells. Cells 8(9):1111","journal-title":"Cells"},{"issue":"10","key":"11349_CR42","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/carcin\/bgaa074","volume":"41","author":"GB Park","year":"2020","unstructured":"Park GB, Jeong JY, Kim D (2020) GLUT5 regulation by AKT1\/3-miR-125b-5p downregulation induces migratory activity and drug resistance in TLR-modified colorectal cancer cells. Carcinogenesis 41(10):1329\u20131340","journal-title":"Carcinogenesis"},{"issue":"49","key":"11349_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201903296","volume":"15","author":"V Juang","year":"2019","unstructured":"Juang V, Chang CH, Wang CS, Wang HE, Lo YL (2019) pH\u2010responsive PEG\u2010shedding and targeting peptide\u2010modified nanoparticles for dual\u2010delivery of irinotecan and microRNA to enhance tumor\u2010specific therapy. Small 15(49):1903296","journal-title":"Small"},{"key":"11349_CR44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00280-019-03975-3","volume":"85","author":"M Poorebrahim","year":"2020","unstructured":"Poorebrahim M, Sadeghi S, Ghanbarian M, Kalhor H, Mehrtash A, Teimoori-Toolabi L (2020) Identification of candidate genes and miRNAs for sensitizing resistant colorectal cancer cells to oxaliplatin and irinotecan. Cancer Chemother Pharmacol 85:153\u2013171","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"11349_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-7-91","volume":"7","author":"C Emmanouilides","year":"2007","unstructured":"Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki A et al (2007) Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer 7(1):91","journal-title":"BMC Cancer"},{"issue":"1","key":"11349_CR46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, Arnold D, Normanno N, Ta\u00efeb J et al (2023) Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34(1):10\u201332","journal-title":"Ann Oncol"},{"issue":"26","key":"11349_CR47","doi-asserted-by":"publisher","first-page":"8409","DOI":"10.7150\/thno.36605","volume":"9","author":"L Sun","year":"2019","unstructured":"Sun L, Fang Y, Wang X, Han Y, Du F, Li C et al (2019) miR-302a inhibits metastasis and cetuximab resistance in colorectal cancer by targeting NFIB and CD44. Theranostics 9(26):8409\u201325","journal-title":"Theranostics"},{"key":"11349_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2019.105643","volume":"118","author":"Y Xing","year":"2020","unstructured":"Xing Y, Jing H, Zhang Y, Suo J, Qian M (2020) MicroRNA-141-3p affected proliferation, chemosensitivity, migration and invasion of colorectal cancer cells by targeting EGFR. Int J Biochem Cell Biol 118:105643","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"11349_CR49","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12935-022-02460-x","volume":"22","author":"H Han","year":"2022","unstructured":"Han H, Li Y, Qin W, Wang L, Yin H, Su B, Yuan X (2022) MiR-199b-3p contributes to acquired resistance to cetuximab in colorectal cancer by targeting CRIM1 via Wnt\/\u03b2-catenin signaling. Cancer Cell Int 22(1):42","journal-title":"Cancer Cell Int"},{"issue":"7","key":"11349_CR50","doi-asserted-by":"publisher","first-page":"101042831770928","DOI":"10.1177\/1010428317709283","volume":"39","author":"O Fiala","year":"2017","unstructured":"Fiala O, Pitule P, Hosek P, Liska V, Sorejs O, Bruha J et al (2017) The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab. Tumor Biology 39(7):1010428317709283","journal-title":"Tumor Biology"},{"key":"11349_CR51","doi-asserted-by":"crossref","unstructured":"Romero-Lorca A, Novillo A, Gaibar M, Gilsanz MF, Gal\u00e1n M, Beltr\u00e1n L et al (2021) miR-7, miR-10a and miR-143 expression May predict response to bevacizumab plus chemotherapy in patients with metastatic colorectal cancer. Pharmacogenomics Personalized Med 1263\u20131273","DOI":"10.2147\/PGPM.S313594"},{"key":"11349_CR52","doi-asserted-by":"publisher","first-page":"5259","DOI":"10.3748\/wjg.v24.i46.5259","volume":"24","author":"Y Liang","year":"2018","unstructured":"Liang Y, Zhang C, Ming H, Dai D (2018) Identification and prediction of novel non-coding and coding RNA-associated competing endogenous RNA networks in colorectal cancer. World J Gastroenterol 24:5259\u20135270","journal-title":"World J Gastroenterol"},{"issue":"7","key":"11349_CR53","doi-asserted-by":"publisher","first-page":"e18197","DOI":"10.1111\/jcmm.18197","volume":"28","author":"A Khalafizadeh","year":"2024","unstructured":"Khalafizadeh A, Hashemizadegan SD, Shokri F, Bakhshinejad B, Jabbari K, Motavaf M, Babashah S (2024) Competitive endogenous RNA networks: decoding the role of long non-coding RNAs and circular RNAs in colorectal cancer chemoresistance. J Cell Mol Med 28(7):e18197","journal-title":"J Cell Mol Med"},{"key":"11349_CR54","doi-asserted-by":"publisher","first-page":"110570","DOI":"10.1016\/j.biopha.2020.110570","volume":"130","author":"K Raziq","year":"2020","unstructured":"Raziq K, Cai M, Dong K, Wang P, Afrifa J, Fu S (2020) Competitive endogenous network of lncRNA, miRNA, and mRNA in the chemoresistance of Gastrointestinal tract adenocarcinomas. Biomed Pharmacother 130:110570","journal-title":"Biomed Pharmacother"},{"key":"11349_CR55","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.omto.2021.06.012","volume":"23","author":"S-J Gao","year":"2021","unstructured":"Gao S-J, Ren S-N, Liu Y-T, Yan H-W, Chen X-B (2021) Targeting EGFR sensitizes 5-Fu-resistant colon cancer cells through modification of the lncRNA-FGD5-AS1-miR-330-3p-Hexokinase 2 axis. Mol Ther Oncolytics 23:14\u201325","journal-title":"Mol Ther Oncolytics"},{"issue":"9","key":"11349_CR56","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1080\/07357907.2021.1923727","volume":"39","author":"Y Fu","year":"2021","unstructured":"Fu Y, Huang R, Li J, Xie X, Deng Y (2021) LncRNA ENSG00000254615 modulates proliferation and 5-FU resistance by regulating p21 and Cyclin D1 in colorectal cancer. Cancer Invest 39(9):696\u2013710","journal-title":"Cancer Invest"},{"key":"11349_CR57","doi-asserted-by":"publisher","first-page":"109483","DOI":"10.1016\/j.cellsig.2019.109483","volume":"66","author":"Z Jiang","year":"2020","unstructured":"Jiang Z, Li L, Hou Z, Liu W, Wang H, Zhou T et al (2020) LncRNA HAND2-AS1 inhibits 5-fluorouracil resistance by modulating miR-20a\/PDCD4 axis in colorectal cancer. Cell Signal 66:109483","journal-title":"Cell Signal"},{"issue":"1","key":"11349_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3748\/wjg.v29.i1.1","volume":"29","author":"ZD Luo","year":"2023","unstructured":"Luo ZD, Wang YF, Zhao YX, Yu LC, Li T, Fan YJ et al (2023) Emerging roles of non-coding RNAs in colorectal cancer oxaliplatin resistance and liquid biopsy potential. World J Gastroenterol 29(1):1\u201318","journal-title":"World J Gastroenterol"},{"key":"11349_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110329","volume":"128","author":"FF Qi","year":"2020","unstructured":"Qi FF, Yang Y, Zhang H, Chen H (2020) Long non-coding RNAs: key regulators in oxaliplatin resistance of colorectal cancer. Biomed Pharmacother 128:110329","journal-title":"Biomed Pharmacother"},{"key":"11349_CR60","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.abb.2019.01.005","volume":"663","author":"R Gao","year":"2019","unstructured":"Gao R, Fang C, Xu J, Tan H, Li P, Ma L (2019) LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145. Arch Biochem Biophys 663:183\u2013191","journal-title":"Arch Biochem Biophys"},{"issue":"2","key":"11349_CR61","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.dld.2023.06.010","volume":"56","author":"S Zhu","year":"2024","unstructured":"Zhu S, Mao J, Zhang X, Wang P, Zhou Y, Tong J et al (2024) CAF-derived exosomal lncRNA FAL1 promotes chemoresistance to oxaliplatin by regulating autophagy in colorectal cancer. Dig Liver Dis 56(2):330\u201342","journal-title":"Dig Liver Dis"},{"issue":"4","key":"11349_CR62","first-page":"3583","volume":"20","author":"F Sun","year":"2019","unstructured":"Sun F, Liang W, Qian J (2019) The identification of CRNDE, H19, UCA1 and HOTAIR as the key LncRNAs involved in oxaliplatin or Irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis. Mol Med Rep 20(4):3583\u20133596","journal-title":"Mol Med Rep"},{"issue":"4_suppl","key":"11349_CR63","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1200\/jco.2012.30.4_suppl.524","volume":"30","author":"NF Jensen","year":"2012","unstructured":"Jensen NF, Soekilde R, Stenvang J, Nielsen BS, Litman T, Br\u00fcnner N, R\u00f8mer MU (2012) Micrornas related to intrinsic resistance to oxaliplatin and the irinotecan metabolite SN-38 in 10 colorectal cancer cell lines. J Clin Oncol 30(4_suppl):524","journal-title":"J Clin Oncol"},{"issue":"11","key":"11349_CR64","first-page":"2515","volume":"9","author":"W Sun","year":"2019","unstructured":"Sun W, Ren S, Li R, Zhang Q, Song H (2019) LncRNA, a novel target biomolecule, is involved in the progression of colorectal cancer. Am J Cancer Res 9(11):2515\u20132530","journal-title":"Am J Cancer Res"},{"issue":"1","key":"11349_CR65","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7150\/jca.65687","volume":"13","author":"HH Yuan","year":"2022","unstructured":"Yuan HH, Zhang XC, Wei XL, Zhang WJ, Du XX, Huang P et al (2022) LncRNA UCA1 mediates cetuximab resistance in colorectal cancer via the MiR-495 and HGF\/c-MET pathways. J Cancer 13(1):253\u2013267","journal-title":"J Cancer"},{"issue":"1","key":"11349_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-018-0660-6","volume":"18","author":"Y-n Yang","year":"2018","unstructured":"Yang Y-n, Zhang R, Du J-w, Yuan H-h, Li Y-j, Wei X-l et al (2018) Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer. Cancer Cell Int 18(1):164","journal-title":"Cancer Cell Int"},{"key":"11349_CR67","doi-asserted-by":"publisher","first-page":"1147239","DOI":"10.3389\/fonc.2023.1147239","volume":"13","author":"S Chen","year":"2023","unstructured":"Chen S, Lin J, Zhao J, Lin Q, Liu J, Wang Q et al (2023) FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy. Front Oncol 13:1147239","journal-title":"Front Oncol"},{"key":"11349_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100975","volume":"69","author":"Q Wen","year":"2023","unstructured":"Wen Q, Huang M, Xie J, Liu R, Miao Q, Huang J et al (2023) LncRNA SYTL5-OT4 promotes vessel co-option by inhibiting the autophagic degradation of ASCT2. Drug Resist Updat 69:100975","journal-title":"Drug Resist Updat"},{"issue":"3","key":"11349_CR69","doi-asserted-by":"publisher","first-page":"321","DOI":"10.7150\/ijbs.24360","volume":"14","author":"Z Kun-Peng","year":"2018","unstructured":"Kun-Peng Z, Xiao-Long M, Chun-Lin Z (2018) Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1. Int J Biol Sci 14(3):321","journal-title":"Int J Biol Sci"},{"issue":"9","key":"11349_CR70","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1111\/jcmm.15122","volume":"24","author":"M Lai","year":"2020","unstructured":"Lai M, Liu G, Li R, Bai H, Zhao J, Xiao P, Mei J (2020) Hsa_circ_0079662 induces the resistance mechanism of the chemotherapy drug oxaliplatin through the TNF-\u03b1 pathway in human colon cancer. J Cell Mol Med 24(9):5021\u20135027","journal-title":"J Cell Mol Med"},{"key":"11349_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2023.147323","volume":"864","author":"J Li","year":"2023","unstructured":"Li J, Lv J, Chen Y, Li L (2023) Tumor suppressor circPDE4D inhibits the progression of colorectal cancer and regulates oxaliplatin chemoresistance. Gene 864:147323","journal-title":"Gene"},{"issue":"1","key":"11349_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-024-00478-x","volume":"19","author":"Y Geng","year":"2024","unstructured":"Geng Y, Zheng X, Zhang D, Wei S, Feng J, Wang W et al (2024) CircHIF1A induces cetuximab resistance in colorectal cancer by promoting HIF1\u03b1-mediated glycometabolism alteration. Biol Direct 19(1):36","journal-title":"Biol Direct"},{"issue":"7483","key":"11349_CR73","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nature12986","volume":"505","author":"Y Tay","year":"2014","unstructured":"Tay Y, Rinn J, Pandolfi PP (2014) The multilayered complexity of CeRNA crosstalk and competition. Nature 505(7483):344\u2013352","journal-title":"Nature"},{"issue":"9","key":"11349_CR74","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/carcin\/bgac065","volume":"43","author":"F Yao","year":"2022","unstructured":"Yao F, Huang X, Xie Z, Chen J, Zhang L, Wang Q et al (2022) LINC02418 upregulates EPHA2 by competitively sponging miR-372-3p to promote 5-Fu\/DDP chemoresistance in colorectal cancer. Carcinogenesis 43(9):895\u2013907","journal-title":"Carcinogenesis"},{"key":"11349_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118255","volume":"259","author":"M Vaghari-Tabari","year":"2020","unstructured":"Vaghari-Tabari M, Majidinia M, Moein S, Qujeq D, Asemi Z, Alemi F et al (2020) MicroRNAs and colorectal cancer chemoresistance: new solution for old problem. Life Sci 259:118255","journal-title":"Life Sci"},{"issue":"7","key":"11349_CR76","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1111\/jcmm.15070","volume":"24","author":"G Xu","year":"2020","unstructured":"Xu G, Zhu H, Xu J, Wang Y, Zhang Y, Zhang M, Zhu D (2020) Long non-coding RNA POU6F2-AS2 promotes cell proliferation and drug resistance in colon cancer by regulating miR-377\/BRD4. J Cell Mol Med 24(7):4136\u20134149","journal-title":"J Cell Mol Med"},{"issue":"1","key":"11349_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-02881-2","volume":"23","author":"Y-N Ma","year":"2023","unstructured":"Ma Y-N, Hong Y-G, Yu G-Y, Jiang S-y, Zhao B-l, Guo A et al (2023) Retraction note: LncRNA LBX2-AS1 promotes colorectal cancer progression and 5-fluorouracil resistance. Cancer Cell Int 23(1):32","journal-title":"Cancer Cell Int"},{"key":"11349_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100683","volume":"50","author":"W Jiang","year":"2020","unstructured":"Jiang W, Xia J, Xie S, Zou R, Pan S, Wang ZW et al (2020) Long non-coding RNAs as a determinant of cancer drug resistance: towards the overcoming of chemoresistance via modulation of lncRNAs. Drug Resist Updat 50:100683","journal-title":"Drug Resist Updat"},{"key":"11349_CR79","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.2147\/OTT.S188054","volume":"12","author":"Y Li","year":"2019","unstructured":"Li Y, Li C, Li D, Yang L, Jin J, Zhang B (2019) LncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a\/ATG4B pathway. Onco Targets Ther 12:2649\u20132660","journal-title":"Onco Targets Ther"},{"issue":"6","key":"11349_CR80","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/CAD.0000000000001289","volume":"33","author":"W Huang","year":"2022","unstructured":"Huang W, Zhang H, Tian Y, Li Y, Li J, Zhong X, Yuan X (2022) LncRNA SNHG11 enhances bevacizumab resistance in colorectal cancer by mediating miR-1207-5p\/ABCC1 axis. Anticancer Drugs 33(6):575\u2013586","journal-title":"Anticancer Drugs"},{"key":"11349_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154227","volume":"240","author":"C Gao","year":"2022","unstructured":"Gao C, Hu W, Zhao J, Ni X, Xu Y (2022) LncRNA HCG18 promotes M2 macrophage polarization to accelerate cetuximab resistance in colorectal cancer through regulating miR-365a-3p\/FOXO1\/CSF-1 axis. Pathol Res Pract 240:154227","journal-title":"Pathol Res Pract"},{"key":"11349_CR82","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3389\/fonc.2020.00291","volume":"10","author":"F Wei","year":"2020","unstructured":"Wei F, Wang M, Li Z, Wang Y, Zhou Y (2020) Long Non-coding RNA MIR570MG causes regorafenib resistance in colon cancer by repressing miR-145\/SMAD3 signaling. Front Oncol 10:291","journal-title":"Front Oncol"},{"issue":"11","key":"11349_CR83","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","volume":"122","author":"DS Hong","year":"2020","unstructured":"Hong DS, Kang Y-K, Borad M, Sachdev J, Ejadi S, Lim HY et al (2020) Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer 122(11):1630\u20131637","journal-title":"Br J Cancer"},{"key":"11349_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1297413","volume":"10","author":"X Yang","year":"2024","unstructured":"Yang X, Liang Y, Tong S (2024) Advancing cancer treatment: in vivo delivery of therapeutic small noncoding RNAs. Front Mol Biosci 10:1297413","journal-title":"Front Mol Biosci"},{"issue":"26","key":"11349_CR85","doi-asserted-by":"publisher","first-page":"22996","DOI":"10.18632\/oncotarget.4035","volume":"6","author":"F Simmer","year":"2015","unstructured":"Simmer F, Venderbosch S, Dijkstra JR, Vink-B\u00f6rger EM, Faber C, Mekenkamp LJ et al (2015) Microrna-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer. Oncotarget 6(26):22996\u201323007","journal-title":"Oncotarget"},{"issue":"8","key":"11349_CR86","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1111\/cas.14090","volume":"110","author":"Y Nakagawa","year":"2019","unstructured":"Nakagawa Y, Kuranaga Y, Tahara T, Yamashita H, Shibata T, Nagasaka M et al (2019) Induced miR-31 by 5\u2010fluorouracil exposure contributes to the resistance in colorectal tumors. Cancer Sci 110(8):2540\u20138","journal-title":"Cancer Sci"},{"key":"11349_CR87","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00280-019-03866-7","volume":"84","author":"P Zhao","year":"2019","unstructured":"Zhao P, Ma Y-g, Zhao Y, Liu D, Dai Z-j, Yan C-y, Guan H-t (2019) Microrna-552 deficiency mediates 5-fluorouracil resistance by targeting SMAD2 signaling in DNA-mismatch-repair-deficient colorectal cancer. Cancer Chemother Pharmacol 84:427\u201339","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"11349_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22910","volume":"36","author":"S Pan","year":"2022","unstructured":"Pan S, Bao D, Li Y, Liu D, Quan S, Wang R (2022) SOX4 induces drug resistance of colorectal cancer cells by downregulating CYLD through transcriptional activation of microrna-17. J Biochem Mol Toxicol 36(1):e22910","journal-title":"J Biochem Mol Toxicol"},{"issue":"8","key":"11349_CR89","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1007\/s11033-023-08451-z","volume":"50","author":"M Valizadeh","year":"2023","unstructured":"Valizadeh M, Babaei E, Sharifi R, Yazdanbod A (2023) Restoration of miR-650 leads to down-regulation of KISS1, a possible route involved in overcoming 5-FU resistance and induction of apoptosis in CRC cells in-vitro. Mol Biol Rep 50(8):6591\u20136599","journal-title":"Mol Biol Rep"},{"issue":"8","key":"11349_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.166821","volume":"1869","author":"H Wang","year":"2023","unstructured":"Wang H, Liang Y, Zhao L, Deng J, Li Y, Zhao H et al (2023) miR-653-3p promotes genomic instability of colorectal cancer cells via targeting SIRT1\/TWIST1 signaling pathway. Biochimica et Biophysica Acta (BBA) 1869(8):166821","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"1","key":"11349_CR91","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2023.2235770","volume":"24","author":"XW Wang","year":"2023","unstructured":"Wang XW, Jiang YH, Ye W, Shao CF, Xie JJ, Li X (2023) SIRT1 promotes the progression and chemoresistance of colorectal cancer through the p53\/miR-101\/KPNA3 axis. Cancer Biol Ther 24(1):2235770","journal-title":"Cancer Biol Ther"},{"issue":"8","key":"11349_CR92","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/jpp\/rgab031","volume":"73","author":"Y Liu","year":"2021","unstructured":"Liu Y, Wang G, Li Y, Zhao Q, Fan L, Tan B et al (2021) miR-424-5p reduces 5-fluorouracil resistance possibly by inhibiting Src\/focal adhesion kinase signalling-mediated epithelial\u2013mesenchymal transition in colon cancer cells. J Pharm Pharmacol 73(8):1062\u201370","journal-title":"J Pharm Pharmacol"},{"issue":"11","key":"11349_CR93","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/abbs\/gmab124","volume":"53","author":"R Hua","year":"2021","unstructured":"Hua R, Zhang Y, Yan X, Tang D, Li X, Ni Q et al (2021) Syndecan-2, negatively regulated by miR-20b-5p, contributes to 5-fluorouracil resistance of colorectal cancer cells via the JNK\/ERK signaling pathway. Acta Biochim Biophys Sin 53(11):1547\u201357","journal-title":"Acta Biochim Biophys Sin"},{"issue":"28","key":"11349_CR94","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1038\/s41388-021-01898-z","volume":"40","author":"H Wang","year":"2021","unstructured":"Wang H, Wang X, Zhang H, Deng T, Liu R, Liu Y et al (2021) The HSF1\/miR-135b-5p axis induces protective autophagy to promote oxaliplatin resistance through the MUL1\/ULK1 pathway in colorectal cancer. Oncogene 40(28):4695\u2013708","journal-title":"Oncogene"},{"issue":"12","key":"11349_CR95","first-page":"6011","volume":"13","author":"YC Su","year":"2023","unstructured":"Su YC, Metzen LT, V\u00e9lez LM, Bournique E, Seldin M, Buisson R et al (2023) Induction of resistance to oxaliplatin in cancer by a microRNA\/Fem1B\/Gli1 pathway. Am J Cancer Res 13(12):6011\u20136025","journal-title":"Am J Cancer Res"},{"issue":"7","key":"11349_CR96","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s12094-019-02237-1","volume":"22","author":"Y Xu","year":"2020","unstructured":"Xu Y, Zhu M (2020) Novel exosomal miR-46146 transfer oxaliplatin chemoresistance in colorectal cancer. Clin Transl Oncol 22(7):1105\u20131116","journal-title":"Clin Transl Oncol"},{"key":"11349_CR97","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.biopha.2018.10.080","volume":"109","author":"L Shi","year":"2019","unstructured":"Shi L, Xi J, Xu X, Peng B, Zhang B (2019) Mir-148a suppressed cell invasion and migration via targeting WNT10b and modulating \u03b2-catenin signaling in cisplatin-resistant colorectal cancer cells. Biomed Pharmacother 109:902\u2013909","journal-title":"Biomed Pharmacother"},{"issue":"null","key":"11349_CR98","doi-asserted-by":"publisher","first-page":"7571","DOI":"10.2147\/OTT.S258727","volume":"13","author":"Z Xian","year":"2020","unstructured":"Xian Z, Hu B, Wang T, Zeng J, Cai J, Zou Q, Zhu P (2020) LncRNA UCA1 contributes to 5-Fluorouracil resistance of colorectal cancer cells through miR-23b-3p\/ZNF281 axis. OncoTargets Therapy 13(null):7571\u20137583","journal-title":"OncoTargets Therapy"},{"key":"11349_CR99","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S239432","author":"X Wang","year":"2020","unstructured":"Wang X, Jiang G, Ren W, Wang B, Yang C, Li M (2020) LncRNA NEAT1 regulates 5-Fu sensitivity, apoptosis and invasion in colorectal cancer through the MiR-150-5p\/CPSF4 axis. OncoTargets Ther. https:\/\/doi.org\/10.2147\/OTT.S239432","journal-title":"OncoTargets Ther"},{"issue":"1","key":"11349_CR100","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12935-019-0951-6","volume":"19","author":"X Wang","year":"2019","unstructured":"Wang X, Lan Z, He J, Lai Q, Yao X, Li Q et al (2019) Lncrna SNHG6 promotes chemoresistance through ULK1-induced autophagy by sponging miR-26a-5p in colorectal cancer cells. Cancer Cell Int 19(1):234","journal-title":"Cancer Cell Int"},{"key":"11349_CR101","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.omto.2021.01.003","volume":"20","author":"L Qu","year":"2021","unstructured":"Qu L, Chen Y, Zhang F, He L (2021) The lncrna DLGAP1-AS1\/miR-149-5p\/TGFB2 axis contributes to colorectal cancer progression and 5-FU resistance by regulating smad2 pathway. Mol Ther Oncolytics 20:607\u2013624","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"11349_CR102","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1186\/s12935-021-02353-5","volume":"21","author":"J Wang","year":"2021","unstructured":"Wang J, Zhang X, Zhang J, Chen S, Zhu J, Wang X (2021) Long noncoding RNA CRART16 confers 5-FU resistance in colorectal cancer cells by sponging miR-193b-5p. Cancer Cell Int 21(1):638","journal-title":"Cancer Cell Int"},{"issue":"19","key":"11349_CR103","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.7150\/jca.32065","volume":"10","author":"M Wang","year":"2019","unstructured":"Wang M, Hu H, Wang Y, Huang Q, Huang R, Chen Y et al (2019) Long non-coding RNA TUG1 mediates 5-fluorouracil resistance by acting as a CeRNA of miR-197-3p in colorectal cancer. J Cancer 10(19):4603\u20134613","journal-title":"J Cancer"},{"issue":"5","key":"11349_CR104","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1002\/cam4.1809","volume":"8","author":"H Wu","year":"2019","unstructured":"Wu H, Zou Q, He H, Liang Y, Lei M, Zhou Q et al (2019) Long non-coding RNA PCAT6 targets miR-204 to modulate the chemoresistance of colorectal cancer cells to 5-fluorouracil-based treatment through HMGA2 signaling. Cancer Med 8(5):2484\u201395","journal-title":"Cancer Med"},{"issue":"1","key":"11349_CR105","doi-asserted-by":"publisher","DOI":"10.1186\/s12860-019-0188-1","volume":"20","author":"C Yang","year":"2019","unstructured":"Yang C, Pan Y, Deng SP (2019) Downregulation of lncRNA CCAT1 enhances 5-fluorouracil sensitivity in human colon cancer cells. BMC Mol Cell Biol 20(1):9","journal-title":"BMC Mol Cell Biol"},{"issue":"7","key":"11349_CR106","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1002\/cam4.3777","volume":"10","author":"ZL Zeng","year":"2021","unstructured":"Zeng ZL, Lu JH, Wang Y, Sheng H, Wang YN, Chen ZH et al (2021) The lncRNA XIST\/miR-125b-2-3p axis modulates cell proliferation and chemotherapeutic sensitivity via targeting Wee1 in colorectal cancer. Cancer Med 10(7):2423\u201341","journal-title":"Cancer Med"},{"key":"11349_CR107","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S313905","author":"M Cai","year":"2021","unstructured":"Cai M, Hu W, Huang C, Zhou C, Li J, Chen Y, Yu Y (2021) LncRNA MCF2L-AS1\/miR-105\/IL-1\u03b2 axis regulates colorectal cancer cell oxaliplatin resistance. Cancer Manag Res. https:\/\/doi.org\/10.2147\/CMAR.S313905","journal-title":"Cancer Manag Res"},{"issue":"12","key":"11349_CR108","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1038\/mt.2016.180","volume":"24","author":"B Yue","year":"2016","unstructured":"Yue B, Cai D, Liu C, Fang C, Yan D (2016) Linc00152 functions as a competing endogenous RNA to confer oxaliplatin resistance and holds prognostic values in colon cancer. Mol Ther 24(12):2064\u20132077","journal-title":"Mol Ther"},{"key":"11349_CR109","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s12935-020-01549-5","volume":"20","author":"C Fan","year":"2020","unstructured":"Fan C, Yuan Q, Liu G, Zhang Y, Yan M, Sun Q, Zhu C (2020) Long non-coding RNA MALAT1 regulates oxaliplatin-resistance via miR-324-3p\/ADAM17 axis in colorectal cancer cells. Cancer Cell Int 20:473","journal-title":"Cancer Cell Int"},{"issue":"1","key":"11349_CR110","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41420-022-01096-0","volume":"8","author":"X Weng","year":"2022","unstructured":"Weng X, Liu H, Ruan J, Du M, Wang L, Mao J et al (2022) HOTAIR\/miR-1277-5p\/ZEB1 axis mediates hypoxia-induced oxaliplatin resistance via regulating epithelial-mesenchymal transition in colorectal cancer. Cell Death Discov 8(1):310","journal-title":"Cell Death Discov"},{"key":"11349_CR111","doi-asserted-by":"publisher","first-page":"13137","DOI":"10.2147\/CMAR.S274447","volume":"12","author":"R Chen","year":"2020","unstructured":"Chen R, Zhou S, Chen J, Lin S, Ye F, Jiang P (2020) LncRNA BLACAT1\/miR-519d-3p\/CREB1 axis mediates proliferation, apoptosis, migration, invasion, and drug-resistance in colorectal cancer progression. Cancer Manag Res 12:13137\u201313148","journal-title":"Cancer Manag Res"},{"issue":"4","key":"11349_CR112","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1158\/1535-7163.MCT-16-0591","volume":"16","author":"P Li","year":"2017","unstructured":"Li P, Zhang X, Wang H, Wang L, Liu T, Du L et al (2017) MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. Mol Cancer Ther 16(4):739\u201351","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"11349_CR113","doi-asserted-by":"publisher","first-page":"347","DOI":"10.15283\/ijsc19041","volume":"12","author":"S Wang","year":"2019","unstructured":"Wang S, Li J, Yang X (2019) Long non-coding RNA LINC00525 promotes the stemness and chemoresistance of colorectal cancer by targeting miR-507\/ELK3 axis. Int J Stem Cells 12(2):347\u201359","journal-title":"Int J Stem Cells"},{"issue":"1","key":"11349_CR114","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12943-017-0583-1","volume":"16","author":"P Han","year":"2017","unstructured":"Han P, Li JW, Zhang BM, Lv JC, Li YM, Gu XY et al (2017) The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt\/\u03b2-catenin signaling. Mol Cancer 16(1):9","journal-title":"Mol Cancer"},{"issue":"1","key":"11349_CR115","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12935-020-1155-9","volume":"20","author":"X Zhang","year":"2020","unstructured":"Zhang X, Wen L, Chen S, Zhang J, Ma Y, Hu J et al (2020) The novel long noncoding RNA CRART16 confers cetuximab resistance in colorectal cancer cells by enhancing ERBB3 expression via miR-371a-5p. Cancer Cell Int 20(1):68","journal-title":"Cancer Cell Int"},{"issue":"16","key":"11349_CR116","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.2217\/epi-2021-0130","volume":"13","author":"Y-J Xu","year":"2021","unstructured":"Xu Y-J, Zhao J-M, Ni X-F, Wang W, Hu W-W, Wu C-P (2021) LncRNA HCG18 suppresses CD8\u2009+\u2009T cells to confer resistance to cetuximab in colorectal cancer via miR-20b-5p\/PD-L1 axis. Epigenomics 13(16):1283\u20131299","journal-title":"Epigenomics"},{"issue":"1","key":"11349_CR117","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7150\/jca.65687","volume":"13","author":"H-H Yuan","year":"2022","unstructured":"Yuan H-H, Zhang X-C, Wei X-L, Zhang W-J, Du X-X, Huang P et al (2022) (2022) LncRNA UCA1 mediates Cetuximab resistance in Colorectal Cancer via the MiR-495 and HGF\/c-MET Pathways. J Cancer [Internet] 13(1):253\u201367","journal-title":"J Cancer [Internet]"},{"issue":"11","key":"11349_CR118","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/nm.4424","volume":"23","author":"Y Lu","year":"2017","unstructured":"Lu Y, Zhao X, Liu Q, Li C, Graves-Deal R, Cao Z et al (2017) LncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt\/\u03b2-catenin signaling. Nat Med 23(11):1331\u201341","journal-title":"Nat Med"},{"issue":"5","key":"11349_CR119","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/jgh.15829","volume":"37","author":"W Wang","year":"2022","unstructured":"Wang W, Zhou L, Li Z, Lin G (2022) Circ_0014130 is involved in the drug sensitivity of colorectal cancer through miR-197\u20103p\/PFKFB3 axis. J Gastroenterol Hepatol 37(5):908\u2013918","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"11349_CR120","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00517-20","volume":"41","author":"K Zhao","year":"2021","unstructured":"Zhao K, Cheng X, Ye Z, Li Y, Peng W, Wu Y, Xing C (2021) Exosome-mediated transfer of circ_0000338 enhances 5-fluorouracil resistance in colorectal cancer through regulating microRNA 217 (miR-217) and miR-485-3p. Mol Cell Biol 41(5):e00517-20","journal-title":"Mol Cell Biol"},{"issue":"4","key":"11349_CR121","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3233\/CBM-200023","volume":"29","author":"X He","year":"2020","unstructured":"He X, Ma J, Zhang M, Cui J, Yang H (2020) Circ_0007031 enhances tumor progression and promotes 5-fluorouracil resistance in colorectal cancer through regulating miR-133b\/ABCC5 axis. Cancer Biomark 29(4):531\u2013542","journal-title":"Cancer Biomark"},{"issue":"4","key":"11349_CR122","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.23297","volume":"37","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wang X, Wang S, Liu J, Li R, Li X, Zhang R (2023) Circ-ERBB2 knockdown sensitized colorectal cancer cells to 5\u2010FU via miR\u2010181a\u20105p\/PTEN\/Akt pathway. J Biochem Mol Toxicol 37(4):e23297","journal-title":"J Biochem Mol Toxicol"},{"key":"11349_CR123","doi-asserted-by":"publisher","first-page":"101604","DOI":"10.1016\/j.tranon.2022.101604","volume":"28","author":"H Chen","year":"2023","unstructured":"Chen H, Zhang J, Yang L, Li Y, Wang Z, Ye C (2023) Circ-ZEB1 regulates epithelial-mesenchymal transition and chemotherapy resistance of colorectal cancer through acting on miR-200c-5p. Transl Oncol 28:101604","journal-title":"Transl Oncol"},{"issue":"1","key":"11349_CR124","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03072-9","volume":"23","author":"X-X Qiao","year":"2023","unstructured":"Qiao X-X, Shi H-B, Xiao L (2023) Serum exosomal hsa-circ-0004771 modulates the resistance of colorectal cancer to 5-fluorouracil via regulating miR-653\/ZEB2 signaling pathway. Cancer Cell Int 23(1):243","journal-title":"Cancer Cell Int"},{"key":"11349_CR125","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev","author":"T-J Ren","year":"2020","unstructured":"Ren T-J, Liu C, Hou J-F, Shan F-X (2020) CircDDX17 reduces 5-fluorouracil resistance and hinders tumorigenesis in colorectal cancer by regulating miR-31-5p\/KANK1 axis. European Review for Medical & Pharmacological Sciences. https:\/\/doi.org\/10.26355\/eurrev","journal-title":"European Review for Medical & Pharmacological Sciences"},{"key":"11349_CR126","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S253468","author":"H Chen","year":"2020","unstructured":"Chen H, Pei L, Xie P, Guo G (2020) Circ-PRKDC contributes to 5-fluorouracil resistance of colorectal cancer cells by regulating miR-375\/FOXM1 axis and Wnt\/\u03b2-catenin pathway. OncoTargets Ther. https:\/\/doi.org\/10.2147\/OTT.S253468","journal-title":"OncoTargets Ther"},{"issue":"6","key":"11349_CR127","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/CAD.0000000000001285","volume":"33","author":"Y Gao","year":"2022","unstructured":"Gao Y, Liu C, Xu X, Wang Y, Jiang Y (2022) Circular RNA sterile alpha motif domain containing 4A contributes to cell 5-fluorouracil resistance in colorectal cancer by regulating the miR-545-3p\/6-phosphofructo-2-kinase\/fructose-2, 6-bisphosphataseisotype 3 axis. Anticancer Drugs 33(6):553\u2013563","journal-title":"Anticancer Drugs"},{"key":"11349_CR128","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ebiom.2019.09.051","volume":"48","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Li C, Liu X, Wang Y, Zhao R, Yang Y et al (2019) CircHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637. EBioMedicine 48:277\u2013288","journal-title":"EBioMedicine"},{"issue":"5","key":"11349_CR129","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s11010-022-04551-9","volume":"478","author":"Z Wang","year":"2023","unstructured":"Wang Z, Liu J, Yang T, Wang Q, Liang R, Tang J (2023) Circ_0082182 upregulates the NFIB level via sponging miR-326 to promote oxaliplatin resistance and malignant progression of colorectal cancer cells. Mol Cell Biochem 478(5):1045\u20131057","journal-title":"Mol Cell Biochem"},{"issue":"8","key":"11349_CR130","first-page":"1","volume":"479","author":"L Lv","year":"2023","unstructured":"Lv L, Yi L, Huang B, Zhou C, Zhang L (2023) Hsa_circ_0071589 aggravates stemness and oxaliplatin resistance in colorectal cancer through sponging miR-133b to upregulate SOX13 expression. Mol Cell Biochem 479(8):1\u201314","journal-title":"Mol Cell Biochem"},{"key":"11349_CR131","volume":"42","author":"L Hongyan","year":"2022","unstructured":"Hongyan L, Yijie Z, Honggang Y, Ganggang M (2022) Analysis of the correlation between circular RNA circ_0008274 and cetuximab resistance in colorectal cancer cells. Chin J Dig 42:9","journal-title":"Chin J Dig"},{"issue":"1","key":"11349_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05536-8","volume":"14","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Zheng Y, Liu J, Tang X, Wang Y, Li X et al (2023) CircIFNGR2 enhances proliferation and migration of CRC and induces cetuximab resistance by indirectly targeting KRAS via sponging to MiR-30b. Cell Death Dis 14(1):24","journal-title":"Cell Death Dis"},{"key":"11349_CR133","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S270123","author":"S Li","year":"2020","unstructured":"Li S, Zheng S (2020) Down-regulation of Circ_0032833 sensitizes colorectal cancer to 5-fluorouracil and oxaliplatin partly depending on the regulation of miR-125-5p and MSI1. Cancer Manag Res. https:\/\/doi.org\/10.2147\/CMAR.S270123","journal-title":"Cancer Manag Res"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11349-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11349-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11349-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:03:21Z","timestamp":1765371801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11349-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":133,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11349"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11349-7","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"12 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable to this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"174"}}